Anixa Biosciences to Host an Investor Webcast on June 26, 2025

Rhea-AI Summary

Anixa Biosciences (NASDAQ: ANIX), a biotechnology company specializing in cancer treatment and prevention, has announced an upcoming investor webcast scheduled for June 26, 2025, at 2:00 PM EDT. During the presentation, CEO Dr. Amit Kumar will provide a comprehensive overview of the company's business strategy, therapeutic portfolio, market opportunities, and upcoming milestones. The interactive webcast will include a Q&A session for investors. Pre-registration is required through a provided Zoom link, and a recording of the webcast along with the presentation materials will be made available on Anixa's investor relations website.

SAN JOSE, Calif., June 20, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will host an investor webcast presentation on June 26, 2025 at 2:00 PM EDT.

During the webcast, Dr. Amit Kumar, Anixa's Chairman and CEO, will conduct an introductory presentation that will cover key aspects of Anixa's business including an overview of the Company's therapeutic portfolio, its business strategy, market opportunity and near-term milestones. After the formal presentation, investors will have an opportunity to ask relevant questions through an interactive Q&A portal.

To listen to the webcast or to ask questions during the live event, please pre-register at the following link: https://us02web.zoom.us/webinar/register/WN_g8ClEi_KQzmPJhIvQdD64Q.

An archived version of the webcast and presentation will be available on the Company's website, https://ir.anixa.com/events.

About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook and YouTube.

Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808

View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-to-host-an-investor-webcast-on-june-26-2025-302486718.html

SOURCE Anixa Biosciences, Inc.

FAQ

When is Anixa Biosciences (ANIX) hosting its investor webcast in 2025?

Anixa Biosciences is hosting its investor webcast on June 26, 2025 at 2:00 PM EDT.

What topics will be covered in Anixa Biosciences' (ANIX) June 2025 investor webcast?

The webcast will cover Anixa's therapeutic portfolio, business strategy, market opportunity, and near-term milestones, presented by CEO Dr. Amit Kumar.

How can investors participate in Anixa Biosciences' (ANIX) June 2025 webcast?

Investors must pre-register through the provided Zoom link to participate in the webcast and ask questions during the Q&A session.

Where can I find the recording of Anixa Biosciences' (ANIX) June 2025 investor webcast?

An archived version of the webcast and presentation will be available on Anixa's website at https://ir.anixa.com/events.